MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management said support at least 12 months of operating runway.
On the company’s first-quarter conference call, President and Chief Executive Officer Dr. Jennifer Buell said MiNK has recently presented data across multiple scientific meetings, including findings in pulmonary fibrosis, refractory gastric cancer and mechanistic work involving its lead iNKT cell therapy candidate, AGENT-797.
